ARTICLE | Clinical News

Latuda lurasidone regulatory update

April 14, 2014 7:00 AM UTC

Health Canada approved Latuda lurasidone to treat depressive episodes associated with bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate. FDA approved Latuda for the indication last July. The product is also approved in the U.S., Canada, EU and Australia to treat schizophrenia. Dainippon's Sunovion Pharmaceuticals Inc. subsidiary markets Latuda in the U.S. and Canada. ...